Extract
In this issue of the European Respiratory Review (ERR), we are delighted to publish a series of articles on rare pulmonary diseases discussing hot topics presented at the 8th International Meeting on Pulmonary Rare Diseases and Orphan Drugs, which took place in Milan, Italy in March 2019. The meeting was endorsed by the European Respiratory Society and the European Reference Network – LUNG; a network of healthcare providers dedicated to the care and investigation of patients suffering from rare respiratory diseases approved by the European Commission's Board of Member States in December 2016 (https://ec.europa.eu/health/ern/networks_en) [1].
Abstract
The interest in rare diseases is growing. The progress in this field has been made possible by a coordinated action between respiratory researchers, health authorities and patients associations. http://bit.ly/2kIurPH
Footnotes
Provenance: Commissioned article, peer reviewed.
Conflict of interest: S. Harari reports grants and personal fees from Roche, Actelion and Boehringer Ingelheim, outside the submitted work.
Conflict of interest: Y. Adir reports grants and personal fees from Actelion and GSK, and personal fees from Sanofi, Merck, United Therapeutics, BI and AstraZeneca, outside the submitted work.
Conflict of interest: M. Humbert reports personal fees from Actelion and Merck, grants and personal fees from Bayer, GSK and United Therapeutics, outside the submitted work.
- Received September 5, 2019.
- Accepted September 12, 2019.
- Copyright ©ERS 2019.
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.